Regeneron presents an interesting investment case. Its valuation doesn't fully capture Dupixent's strength or its pipeline potential. Bears worry about Eylea's patent cliff, but this seems priced in.

The Proteus Syndrome market is entering a pivotal decade, driven by increasing disease recognition, improving diagnostic techniques, development of genetic testing techniques and other innovative ...

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...